Joseph Sierchio
Directeur/Membre du Conseil chez SOLARWINDOW TECHNOLOGIES, INC.
Fortune : 448 436 $ au 30/04/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Amit Singh Dang | M | 43 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | 5 ans |
Meetesh V. Patel | M | 49 |
BluFlow Technologies, Inc.
BluFlow Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services BluFlow Technologies, Inc. provides business activities. The private company is based in New York, NY. Meetesh V. Patel has been the CEO of the American company since 2010. | 16 ans |
Justin Frere | M | 51 | 13 ans | |
Janet Lynn Bien | F | 60 |
BluFlow Technologies, Inc.
BluFlow Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services BluFlow Technologies, Inc. provides business activities. The private company is based in New York, NY. Meetesh V. Patel has been the CEO of the American company since 2010. | 13 ans |
Briana L. Erickson | F | - | 13 ans | |
Robert Levine | M | 75 | 6 ans | |
Patrick Sargent | M | - | - | |
James L. Bicksler | M | 86 |
Rutgers State University of New Jersey
| 55 ans |
In-Jae Chung | M | 67 | 3 ans | |
James Whitaker | M | - | 5 ans | |
Alexandra Musk | F | - | 4 ans | |
Kyle Ballarta | M | - | 3 ans | |
Chulwoo Kim | M | - | 2 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Harmel Rayat | M | 63 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | 13 ans |
Steven C. Berger | M | 63 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 3 ans |
Derek J. Cooper | M | 48 | 3 ans | |
Jatinder Bhogal | M | 56 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | 11 ans |
John A. Conklin | M | 64 | 10 ans | |
Thomas Bold | M | 62 | 6 ans | |
Rhonda Beth Rosen | F | 67 | 3 ans | |
Antonino Cacace | M | - | - | |
Mike M. Goldberg | M | 65 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 1 ans |
Jerome Zeldis | M | 74 |
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 5 ans |
Joseph M. Leone | M | 70 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | - |
Jeffrey Sklar | M | 61 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | - |
Kenneth D. Pearsen | M | 63 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 3 ans |
Dave Stefansky | M | 52 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 4 ans |
Nachum Stein | M | 75 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 1 ans |
Javier Jimenez | M | 58 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | 5 ans |
Michael Schuler | M | - |
Rutgers State University of New Jersey
| 7 ans |
Richard S. Zackin | M | - |
Rutgers State University of New Jersey
| 6 ans |
Kenneth Kirkland | M | 82 | 8 ans | |
Andrew T. Farago | M | - | 1 ans | |
Vincent A. Cino | M | - |
Rutgers State University of New Jersey
| 10 ans |
Patsy J. Trisler | F | 74 | 6 ans | |
Frank J. Fabio | M | - | 1 ans | |
James Sapirstein | M | 63 |
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 2 ans |
Frank Menzler | M | 55 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | 3 ans |
Peter C. Fusaro | M | 73 | 1 ans | |
Helen M. Galt | F | 76 |
Rutgers State University of New Jersey
| 5 ans |
Roger Esteban-Vives | M | - | 6 ans | |
David Jenkins | M | 70 | 2 ans | |
Gary Parmar | M | 53 | 2 ans | |
Allan Harvey Cohen | M | 73 |
Rutgers State University of New Jersey
| 5 ans |
Kenneth Londoner | M | 57 |
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 2 ans |
Richard Rosenblum | M | 65 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | 1 ans |
Todd M. Pitcher | M | 55 | - | |
Joel S. Becker | M | 75 |
Rutgers State University of New Jersey
| 4 ans |
Sol Barer | M | 76 |
Rutgers State University of New Jersey
| 3 ans |
Kenneth J. Frank | M | 77 |
Rutgers State University of New Jersey
| 4 ans |
Joseph Spitzner | M | - |
Rutgers State University of New Jersey
| 3 ans |
Katie Tyler | F | - |
Rutgers State University of New Jersey
| 4 ans |
Harry Jay Levin | M | - |
Rutgers State University of New Jersey
| 4 ans |
Lawrence Burrows | M | 71 |
Rutgers State University of New Jersey
| 3 ans |
Thomas Peter Monahan | M | 76 |
Rutgers State University of New Jersey
| 4 ans |
Ernie G. Jacob | M | - |
Rutgers State University of New Jersey
| 4 ans |
Dave M. Reicher | M | - |
Rutgers State University of New Jersey
| 4 ans |
Tom Nugent | M | 82 |
Rutgers State University of New Jersey
| 2 ans |
Glenn L. Noland | M | - |
Rutgers State University of New Jersey
| 4 ans |
Jerry Israel | M | 81 |
Rutgers State University of New Jersey
| 3 ans |
Robert W. Kortmann | M | - |
Rutgers State University of New Jersey
| 4 ans |
Steven Sanders | M | 78 |
Cornell Law School
| 3 ans |
Len Krietz | M | - |
Rutgers State University of New Jersey
| 4 ans |
Scott R. Randall | M | - |
Rutgers State University of New Jersey
| 4 ans |
Deborah French McCay | M | - |
Rutgers State University of New Jersey
| 4 ans |
Louis J. Freeh | M | 74 |
Rutgers State University of New Jersey
| 4 ans |
Richard S. Heller | M | - |
Rutgers State University of New Jersey
| 4 ans |
Barry Frankel | M | 73 |
Rutgers State University of New Jersey
| 4 ans |
Steven W. Pasko | M | 75 |
Rutgers State University of New Jersey
| 4 ans |
Robert Druskin | M | 76 |
Rutgers State University of New Jersey
| 4 ans |
Thomas Renyi | M | 78 |
Rutgers State University of New Jersey
| 4 ans |
Saul Zimmerman | M | - |
Rutgers State University of New Jersey
| 4 ans |
Jonathan M. Kuller | M | - |
Rutgers State University of New Jersey
| 4 ans |
Bruce Severance | M | - |
Rutgers State University of New Jersey
| 4 ans |
Mack Gill | M | 72 |
Rutgers State University of New Jersey
| 4 ans |
Lorelei C. Koran | F | - |
Rutgers State University of New Jersey
| 4 ans |
Bruce T. Prolow | M | - |
Rutgers State University of New Jersey
| 4 ans |
Richard Berliner | M | 71 |
Rutgers State University of New Jersey
| 4 ans |
Mark K. Tonnesen | M | 72 |
Rutgers State University of New Jersey
| 4 ans |
Thomas R. Brown | M | 73 |
Rutgers State University of New Jersey
| 4 ans |
Beverly W. Aisenbrey | F | - |
Rutgers State University of New Jersey
| 4 ans |
Kenneth C. Huhn | M | - |
Rutgers State University of New Jersey
| 3 ans |
James E. Verzella | M | - |
Rutgers State University of New Jersey
| 4 ans |
Douglas Oliver | M | 71 |
Rutgers State University of New Jersey
| 4 ans |
Douglas A. Duchak | M | - |
Rutgers State University of New Jersey
| 4 ans |
Gary Crawford | M | - |
Rutgers State University of New Jersey
| 4 ans |
Melvin Keating | M | 77 |
Rutgers State University of New Jersey
| 4 ans |
David E. Politziner | M | - |
Rutgers State University of New Jersey
| 4 ans |
Robert Tomasetti | M | - |
Rutgers State University of New Jersey
| 4 ans |
Phil Rosenbaum | M | - |
Rutgers State University of New Jersey
| 4 ans |
Gerald C. Harvey | M | 74 |
Rutgers State University of New Jersey
| 4 ans |
David A. Weber | M | 70 |
Rutgers State University of New Jersey
| 4 ans |
Stephen L. Newman | M | 73 |
Rutgers State University of New Jersey
| 4 ans |
Douglas B. Campbell | M | - |
Rutgers State University of New Jersey
| 4 ans |
Mark S. Geraghty | M | - |
Rutgers State University of New Jersey
| 3 ans |
Peter Charles Schultz | M | - |
Rutgers State University of New Jersey
| 3 ans |
Andrew R. Jordan | M | - |
Rutgers State University of New Jersey
| 2 ans |
Frank Filipps | M | 76 |
Rutgers State University of New Jersey
| 4 ans |
Brian R. Burr | M | - |
Rutgers State University of New Jersey
| 4 ans |
Ernest Edwards | M | - |
Rutgers State University of New Jersey
| 4 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 100 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Joseph Sierchio
- Réseau Personnel